Loading…
Employees: 1,461
Size Orchid Pharma (ORCHPHARMA.NS) is an India Health Care company (Pharmaceuticals: Major) with a market value of $551M, the 805th largest of 1,058 India companies the cockpit tracks. Shares closed at ₹868.00 on 6 Nov 2026.
Performance Over six months the shares gained 27.3%, against -13.9% for the median peer and 0.0% for the India market (cap-weighted) — 5th highest of 21 in its peer set.
Growth Revenue grew 10.8% over the last twelve months (peer median +9.8%); the operating margin is 0.3% (peer median 10.6%).
Valuation It trades at 75.5× forward earnings against a peer median of 14.9× (most expensive of 6).
Capital Return on invested capital runs 18.8 points below its cost of capital (19.0% WACC).
Next results Next results expected around 16 Nov 2026 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | ₹9.43B | ₹12.3B | ₹13.9B | ₹8.19B | ₹6.66B |
| Revenue growth | — | -12% | +70% | +23% | — |
| Gross profit | ₹1.76B | ₹867M | ₹1.98B | ₹1.36B | ₹707M |
| EBITDA | ₹410M | ₹462M | ₹1.48B | ₹1.11B | ₹845M |
| Net income | ₹86.7M | ₹99.6M | ₹1.35B | ₹922M | ₹463M |
| Free cash flow | n/a | -₹2.62B | -₹940M | ₹568M | -₹983M |
| Capital expenditure | n/a | ₹3.90B | ₹1.54B | ₹648M | ₹849M |
| Total debt | n/a | ₹3.07B | ₹1.54B | ₹2.04B | ₹4.00B |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | ORCHPHARMA.NS | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -15.2% | -7.8% | 7th lowest of 21 |
| 6-month return | +27.3% | -13.9% | 5th highest of 21 |
| Distance from 52-week high | -24.1% | -32.1% | 6th highest of 21 |
| Revenue growth (TTM) | +10.8% | +9.8% | 10th highest of 20 |
| Operating margin | 0.3% | 10.6% | 7th lowest of 18 |
| Forward P/E | 75.5× | 14.9× | most expensive of 6 |
| ROIC minus cost of capital | -18.8 pp | -2.6 pp | 4th lowest of 19 |
| Net debt / EBITDA | 5.5× | 0.3× | most indebted of 6 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Orchid Pharma ORCHPHARMA.NS | India | $551M | +27% | +11% | 0% | 75.5× | n/a | n/a |
| Chimin Health Management 603222.SS | China | $553M | -28% | +1% | -28% | n/a | n/a | n/a |
| Entera Bio ENTX | United States | $546M | +142% | -100% | n/a | n/a | n/a | n/a |
| Jiangsu Lianhuan Pharmaceutical 600513.SS | China | $546M | -44% | +14% | 0% | n/a | n/a | n/a |
| Ovid Therapeutics OVID | United States | $557M | +2% | -76% | -3,687% | n/a | n/a | n/a |
| Shanghai Xiao Fang Pharmaceutical 603207.SS | China | $544M | -14% | +10% | 39% | n/a | -3.9% | +7.6% |
| Zeria Pharmaceutical 4559.T | Japan | $540M | -6% | +12% | 15% | 9.3× | -12.5% | +11.1% |
| Xizang Weixinkang Pharmaceutical 603676.SS | China | $538M | -22% | -8% | 16% | n/a | -5.2% | +9.6% |
| Beijing Science Sun Pharmaceutical 300485.SZ | China | $566M | -28% | -11% | -8% | n/a | n/a | n/a |
| Senores Pharmaceuticals SENORES.NS | India | $566M | +25% | +40% | 24% | 34.2× | n/a | n/a |
| ChengDa PharmaCeuticals 301201.SZ | China | $535M | -43% | +27% | -9% | n/a | n/a | n/a |
| Henan Taloph Pharmaceutical Stock 600222.SS | China | $533M | -5% | -5% | 7% | n/a | 17.7% | +4.4% |
| Boryung 003850.KS | South Korea | $531M | -14% | +6% | 6% | 11.1× | -8.9% | +12.6% |
| Bicara Therapeutics BCAX | United States | $572M | -62% | n/a | n/a | n/a | n/a | n/a |
| Nanjing Hicin Pharmaceutical 300584.SZ | China | $573M | -25% | +32% | 17% | n/a | 5.5% | -1.1% |
| Morepen Laboratories MOREPENLAB.NS | India | $529M | +110% | +30% | 11% | n/a | n/a | n/a |
| Egetis Therapeutics EGTX.ST | Sweden | $528M | +67% | +39% | -604% | 14.9× | n/a | n/a |
| Handa Pharmaceuticals 6620.TWO | Taiwan | $525M | +43% | +68% | 37% | 21.6× | 12.9% | +126.7% |
| Gujarat Themis Biosyn GUJTHEM.NS | India | $524M | -5% | +18% | 39% | n/a | n/a | n/a |
| Newland Pharmaceutical 301277.SZ | China | $523M | -22% | +9% | 11% | n/a | 10.2% | +9.1% |
| Capricor Therapeutics CAPR | United States | $523M | -73% | -100% | n/a | n/a | n/a | n/a |